ArticleBiomedical chromatography : BMC2026
Serum and Urine Metabolite Profiling Combined With Network Pharmacology to Predict the Renoprotective Mechanism of Huangkui Capsule Against Acute Kidney Injury.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Huangkui capsule (HKC), the ethanol extract of Abelmoschus Manihot (L.) Medicus, is well known for its nephroprotective effects against chronic kidney diseases, but its therapeutic potential in acute kidney injury (AKI) and the underlying mechanisms remain largely unexplored. In this study, a simple and reliable LC-Q-TOF/MS method was developed to detect HKC metabolites in rat serum and urine. A metabolite-disease target network was constructed to predict the pharmacological activities of the serum metabolites, followed by PPI network analysis for hub target identification and GO/KEGG enrichment analyses. A total of 41 urine and 28 serum metabolites were identified. Network pharmacology analysis revealed 50 targets associated with 15 metabolites in the context of HKC treatment of AKI. AKT1 and its related pathways were predicted to serve as a central hub, and molecular docking analysis further predicted favorable binding affinity between AKT1 and all six screened key metabolites. This study established a practical approach for identifying HKC metabolites in vivo and provided a systematic framework for predicting the anti-AKI mechanism of HKC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.